EMERYVILLE, California., March 3, 2020 / PRNewswire / – Profusa, a pioneering digital health company in the next generation of personalized medicine, today announced the launch of a study that will use the company’s Lumee minimally invasive injectable biosensor technology® Oxygen platform, as a platform that can potentially help in the early detection of influenza outbreaks. The study is part of a collaboration with RTI International, a non-profit research institute developing algorithms for disease detection, and research centers including duke university and Imperial College London.
The study, conducted at Imperial College London, will examine how sensors monitoring physiological status, including the Lumee oxygen platform that measures tissue oxygen levels, provide potential indicators of human response infection or exposure to disease in healthy volunteers. The goal of the study is to develop an early identification system to detect not only disease outbreaks, but biological attacks and pandemics up to three weeks earlier than current methods. The results of the study are expected to be available in 2021.
“This research marks an exciting step in the development of revolutionary preventive care,” said Ben hwang, President and CEO of Profusa. “Lumee’s oxygen platform can potentially function as a sort of canary in a coal mine for infectious diseases, because subtle changes in oxygen in the tissues can signal problems and can help clinicians correct quickly for avoid epidemics. ”
Changes in oxygen levels and other physiological measures, such as heart rate, following a respiratory infection may help study researchers develop algorithms that can detect early and early influenza activity -symptomatic faster than is currently possible.
Despite the availability of antivirals and vaccines, the flu remains one of the leading causes of illness and premature death worldwide. Seasonal flu affects between 10% and 46% of the population each year, with mortality of up to around 12 deaths per 100,000 in developed countries. During the 2009 H1N1 pandemic, many serious cases occurred in previously healthy young adults. With the entire world population potentially at risk, preventing and improving the management of seasonal and pandemic influenza is of paramount importance.
“The potential importance of this new technology should not be underestimated, and Profusa is proud to be part of a joint effort funded by a DARPA, or Defense Advanced Research Research Agency Agency,” said Sean Givens, head of government affairs for Profusa. “This is particularly exciting for Profusa, as we look forward to learning from the lessons for future platform applications.”
Profusa’s Lumee patch, a wireless reader that adheres to the skin and collects and reports tissue oxygen levels detected by the Lumee oxygen sensor to a mobile device for viewing data in real time, will be used in the ‘clinical study.
The Lumee patch and software used in this study have received approval from the Medicines and Health Products Regulatory Agency (MHRA) in the UK as an investigative device for use in conjunction with others devices. The Lumee injectable oxygen sensor and the Lumee Pen injector used in this study are CE marked for use in the European Union and the EEA.
The project is part of DARPA’s SIGMA + program at the Defense Sciences Office (DSO).
Situated at Emeryville, California., Profusa is a digital healthcare company led by visionary scientific founders, an experienced management team and a world-class board of directors who share the long-term goal of improving the health and well-being of patients. whole world. With its durable, injectable and affordable biosensors and its smart data platform, Profusa aims to provide people with a personalized biochemical signature anchored in data that clinicians trust and rely on. This data can enable people to act as an active and educated participant alongside their healthcare team and to understand how their choices and decisions affect health and well-being, day after day.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
About Lumee® Oxygen platform
Profusa’s first clinical offer, the Lumee® Next generation wireless oxygen and Lumee platform® The oxygen platform, which is CE marked for use in the European Union, is indicated for use in patients with potential acute and / or chronic changes in tissue oxygen levels who may benefit from monitoring. The Lumee oxygen sensor allows continuous and long-term monitoring of oxygen in the subcutaneous tissue. After a single injection, the measurement is then obtained non-invasively using an optical reader. Unlike external pulse oximeters, which measure the oxygen bound to hemoglobin in large blood vessels, the Lumee Oxygen platform measures dissolved oxygen in the tissues of the fluid that bathes cells.
About DARPA SIGMA +
The DARPA SIGMA + program aims to extend SIGMA’s advanced capacity to detect illicit radioactive and nuclear materials by developing new sensors and networks that would also alert authorities to chemical, biological and explosive threats.
SIGMA + calls for the development of highly sensitive detectors and advanced intelligence analyzes to detect minute traces of various substances linked to threats of weapons of mass destruction (WMD). SIGMA + will use a common network infrastructure and mobile detection strategy, a concept that has proven itself in the SIGMA program. The high yield chemical, biological, radiological, nuclear and explosive SIGMA + detection network (CBRNE) would be scalable to cover a large metropolis and its surrounding region.
The planned execution of SIGMA + will take place in two phases. Phase 1 will focus on the development of new sensors for chemicals, explosives and biological agents while Phase 2 will focus on the development, analysis and integration of networks.
Funding from the Defense Advanced Research Projects Agency (DARPA). The views, opinions and / or findings expressed are those of the author and should not be construed as representing the official views or policies of the Department of Defense or the United States government..
1 Monto, A. S. Epidemiology of influenza. Vaccine 26 Suppl 4, D45-48 (2008).
SOURCE Profusa, Inc.